Click for best price
Antibodydrug Conjugate for Cancer Market Size, Share 2023
| Market size in 2022 |
US$ 874 million
|
Forecast Market size by 2029 |
US$ 1189.2 million
|
| Growth Rate |
CAGR of 4.5% |
Number of Pages |
60 Pages |
The global Antibody-drug Conjugate for Cancer market was valued at US$ 874 million in 2022 and is projected to reach US$ 1189.2 million by 2029, at a CAGR of 4.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Antibody-drug Conjugate for Cancer market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugate for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugate for Cancer. This report contains market size and forecasts of Antibody-drug Conjugate for Cancer in global, including the following market information:
- Global Antibody-drug Conjugate for Cancer Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
North America is the largest market with about 59% market share. Europe is follower, accounting for about 27% market share.
The key players are ImmunoGen, Seattle Genetics, Roche, Takeda etc. Takeda is the largest manufacturer with about 57% revenue market share.
We surveyed the Antibody-drug Conjugate for Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antibody-drug Conjugate for Cancer Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Type, 2022 (%)
- Hematological Malignancies Drugs
- Solid Tumor Drugs
Global Antibody-drug Conjugate for Cancer Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, by Application, 2022 (%)
Global Antibody-drug Conjugate for Cancer Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Antibody-drug Conjugate for Cancer Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Antibody-drug Conjugate for Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Antibody-drug Conjugate for Cancer revenues share in global market, 2022 (%)
key players include:
- Gilead Sciences
- Roche
- Pfizer
- Takeda
- Seagen
- Innate Pharma
- AstraZeneca
- GSK
- Rakuten Medical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antibody-drug Conjugate for Cancer, market overview.
Chapter 2: Global Antibody-drug Conjugate for Cancer market size in revenue.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antibody-drug Conjugate for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Antibody-drug Conjugate for Cancer Market, Global Outlook and Forecast 2023-2030 |
| Market size in 2022 |
US$ 874 million
|
| Forecast Market size by 2029 |
US$ 1189.2 million
|
| Growth Rate |
CAGR of 4.5% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
60 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Antibody-drug Conjugate for Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antibody-drug Conjugate for Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antibody-drug Conjugate for Cancer Overall Market Size
2.1 Global Antibody-drug Conjugate for Cancer Market Size: 2022 VS 2030
2.2 Global Antibody-drug Conjugate for Cancer Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Antibody-drug Conjugate for Cancer Players in Global Market
3.2 Top Global Antibody-drug Conjugate for Cancer Companies Ranked by Revenue
3.3 Global Antibody-drug Conjugate for Cancer Revenue by Companies
3.4 Top 3 and Top 5 Antibody-drug Conjugate for Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Antibody-drug Conjugate for Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Players in Global Market
3.6.1 List of Global Tier 1 Antibody-drug Conjugate for Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Antibody-drug Conjugate for Cancer Market Size Markets, 2022 & 2030
4.1.2 Hematological Malignancies Drugs
4.1.3 Solid Tumor Drugs
4.2 By Type - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
4.2.1 By Type - Global Antibody-drug Conjugate for Cancer Revenue, 2018-2023
4.2.2 By Type - Global Antibody-drug Conjugate for Cancer Revenue, 2024-2030
4.2.3 By Type - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Antibody-drug Conjugate for Cancer Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Other
5.2 By Application - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
5.2.1 By Application - Global Antibody-drug Conjugate for Cancer Revenue, 2018-2023
5.2.2 By Application - Global Antibody-drug Conjugate for Cancer Revenue, 2024-2030
5.2.3 By Application - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Antibody-drug Conjugate for Cancer Market Size, 2022 & 2030
6.2 By Region - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
6.2.1 By Region - Global Antibody-drug Conjugate for Cancer Revenue, 2018-2023
6.2.2 By Region - Global Antibody-drug Conjugate for Cancer Revenue, 2024-2030
6.2.3 By Region - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Antibody-drug Conjugate for Cancer Revenue, 2018-2030
6.3.2 US Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.3.3 Canada Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.3.4 Mexico Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Antibody-drug Conjugate for Cancer Revenue, 2018-2030
6.4.2 Germany Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.3 France Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.4 U.K. Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.5 Italy Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.6 Russia Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.7 Nordic Countries Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.4.8 Benelux Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Antibody-drug Conjugate for Cancer Revenue, 2018-2030
6.5.2 China Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.5.3 Japan Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.5.4 South Korea Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.5.5 Southeast Asia Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.5.6 India Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Antibody-drug Conjugate for Cancer Revenue, 2018-2030
6.6.2 Brazil Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.6.3 Argentina Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, 2018-2030
6.7.2 Turkey Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.7.3 Israel Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.7.4 Saudi Arabia Antibody-drug Conjugate for Cancer Market Size, 2018-2030
6.7.5 UAE Antibody-drug Conjugate for Cancer Market Size, 2018-2030
7 Antibody-drug Conjugate for Cancer Companies Profiles
7.1 Gilead Sciences
7.1.1 Gilead Sciences Company Summary
7.1.2 Gilead Sciences Business Overview
7.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Major Product Offerings
7.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.1.5 Gilead Sciences Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Antibody-drug Conjugate for Cancer Major Product Offerings
7.2.4 Roche Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Pfizer
7.3.1 Pfizer Company Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Antibody-drug Conjugate for Cancer Major Product Offerings
7.3.4 Pfizer Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.3.5 Pfizer Key News & Latest Developments
7.4 Takeda
7.4.1 Takeda Company Summary
7.4.2 Takeda Business Overview
7.4.3 Takeda Antibody-drug Conjugate for Cancer Major Product Offerings
7.4.4 Takeda Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.4.5 Takeda Key News & Latest Developments
7.5 Seagen
7.5.1 Seagen Company Summary
7.5.2 Seagen Business Overview
7.5.3 Seagen Antibody-drug Conjugate for Cancer Major Product Offerings
7.5.4 Seagen Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.5.5 Seagen Key News & Latest Developments
7.6 Innate Pharma
7.6.1 Innate Pharma Company Summary
7.6.2 Innate Pharma Business Overview
7.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Major Product Offerings
7.6.4 Innate Pharma Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.6.5 Innate Pharma Key News & Latest Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Company Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Major Product Offerings
7.7.4 AstraZeneca Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.7.5 AstraZeneca Key News & Latest Developments
7.8 GSK
7.8.1 GSK Company Summary
7.8.2 GSK Business Overview
7.8.3 GSK Antibody-drug Conjugate for Cancer Major Product Offerings
7.8.4 GSK Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.8.5 GSK Key News & Latest Developments
7.9 Rakuten Medical
7.9.1 Rakuten Medical Company Summary
7.9.2 Rakuten Medical Business Overview
7.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Major Product Offerings
7.9.4 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue in Global Market (2018-2023)
7.9.5 Rakuten Medical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Antibody-drug Conjugate for Cancer Market Opportunities & Trends in Global Market
Table 2. Antibody-drug Conjugate for Cancer Market Drivers in Global Market
Table 3. Antibody-drug Conjugate for Cancer Market Restraints in Global Market
Table 4. Key Players of Antibody-drug Conjugate for Cancer in Global Market
Table 5. Top Antibody-drug Conjugate for Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Antibody-drug Conjugate for Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Antibody-drug Conjugate for Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Antibody-drug Conjugate for Cancer Product Type
Table 9. List of Global Tier 1 Antibody-drug Conjugate for Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Antibody-drug Conjugate for Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Antibody-drug Conjugate for Cancer Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2024-2030
Table 30. Gilead Sciences Company Summary
Table 31. Gilead Sciences Antibody-drug Conjugate for Cancer Product Offerings
Table 32. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Gilead Sciences Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Antibody-drug Conjugate for Cancer Product Offerings
Table 36. Roche Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. Roche Key News & Latest Developments
Table 38. Pfizer Company Summary
Table 39. Pfizer Antibody-drug Conjugate for Cancer Product Offerings
Table 40. Pfizer Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Pfizer Key News & Latest Developments
Table 42. Takeda Company Summary
Table 43. Takeda Antibody-drug Conjugate for Cancer Product Offerings
Table 44. Takeda Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Takeda Key News & Latest Developments
Table 46. Seagen Company Summary
Table 47. Seagen Antibody-drug Conjugate for Cancer Product Offerings
Table 48. Seagen Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Seagen Key News & Latest Developments
Table 50. Innate Pharma Company Summary
Table 51. Innate Pharma Antibody-drug Conjugate for Cancer Product Offerings
Table 52. Innate Pharma Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Innate Pharma Key News & Latest Developments
Table 54. AstraZeneca Company Summary
Table 55. AstraZeneca Antibody-drug Conjugate for Cancer Product Offerings
Table 56. AstraZeneca Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. AstraZeneca Key News & Latest Developments
Table 58. GSK Company Summary
Table 59. GSK Antibody-drug Conjugate for Cancer Product Offerings
Table 60. GSK Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. GSK Key News & Latest Developments
Table 62. Rakuten Medical Company Summary
Table 63. Rakuten Medical Antibody-drug Conjugate for Cancer Product Offerings
Table 64. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue (US$, Mn) & (2018-2023)
Table 65. Rakuten Medical Key News & Latest Developments
List of Figures
Figure 1. Antibody-drug Conjugate for Cancer Segment by Type in 2022
Figure 2. Antibody-drug Conjugate for Cancer Segment by Application in 2022
Figure 3. Global Antibody-drug Conjugate for Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Antibody-drug Conjugate for Cancer Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Antibody-drug Conjugate for Cancer Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antibody-drug Conjugate for Cancer Revenue in 2022
Figure 8. By Type - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 9. By Application - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 10. By Type - Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 12. By Application - Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 14. By Region - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 15. By Country - North America Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 16. US Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 20. Germany Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 21. France Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 28. China Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 32. India Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 34. Brazil Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue Market Share, 2018-2030
Figure 37. Turkey Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2018-2030
Figure 41. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Roche Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Pfizer Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Takeda Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Seagen Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Innate Pharma Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. AstraZeneca Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. GSK Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
